PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Covarrubias AJ, Perrone R, Grozio A, et al. Nat Rev Mol Cell Biol. 2021
Compare
NAD+ vs PT-141
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
NAD+
96 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 98% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
197
Appetite
197
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
66
Nausea
64
Injection site irritation
64
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
2
0.2–0.4 mg
17
0.4–0.6 mg
8
0.6–1 mg
1
1–2 mg
2
3–5 mg
2
5+ mg
165
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 51 days · Based on 42 repeat reporters
PT-141
29 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 4% · Mixed 3% · Unfavorable overall 93%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Libido
115
Mood
2
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
38
Headache
37
Injection site irritation
35
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
1
0.2–0.4 mg
2
0.4–0.6 mg
9
0.6–1 mg
3
1–2 mg
9
2–3 mg
90
5+ mg
1
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 100 days · Based on 23 repeat reporters
Sources (13)
Published sources linked on the NAD+ and PT-141 wiki pages.
- Wiki study page →Source
- Wiki study page →Source
PubMed
Safety and efficacy of NAD+ supplementation: a systematic review
Reiten OK, Wilvang MA, Mitchell SJ, et al. J Clin Invest. 2021
- Wiki study page →Source
PubMed
NAD+ intermediates: The biology and therapeutic potential
Yoshino J, Baur JA, Imai SI. Cell Metab. 2018
- Wiki study page →Source
ClinicalTrials.gov
NAD+ studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns
Bhasin S, Seals D, Migaud M, et al. Endocrine reviews. 2023
- Wiki study page →Source
PubMed
NAD⁺ in aging, metabolism, and neurodegeneration
Verdin E. Science (New York, N.Y.). 2015
- Wiki study page →Source
PubMed
NAD+ and sirtuins in aging and disease
Imai S, Guarente L. Trends in cell biology. 2014
- Wiki study page →Source
PubMed
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
Song Q, Zhou X, Xu K, et al. Advances in nutrition (Bethesda, Md.). 2023
- Wiki study page →Source
FDA Drug Label
VYLEESI (bremelanotide injection) for subcutaneous use - Prescribing Information
AMAG Pharmaceuticals. FDA Drug Label. 2019
- Wiki study page →Source
PubMed
Bremelanotide: New Drug for Treating Hypoactive Sexual Desire Disorder
Kingsberg SA, Clayton AH, Portman D, et al. Obstet Gynecol. 2019
- Wiki study page →Source
ClinicalTrials.gov
Bremelanotide (PT-141) studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment
Pettigrew JA, Novick AM. Journal of midwifery & women's health. 2021
- Wiki study page →Source
PubMed
Pharmacologic therapeutic options for sexual dysfunction
Burton CS, Mishra K. Current opinion in obstetrics & gynecology. 2022